Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
Sign Up to like & getrecommendations! Published in 2018 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-018-4996-3
Abstract: PurposeTo provide dermatologists and oncologists with a foundation for practical understanding and uses of 5α-reductase inhibitors and spironolactone for breast cancer patients and survivors receiving endocrine therapies (ETs), including the effect of these treatments on… read more here.
Keywords: breast cancer; inhibitors spironolactone; cancer; cancer patients ... See more keywords